EBioMedicine (Jan 2018)
HtrA1 Mediated Intracellular Effects on Tubulin Using a Polarized RPE Disease Model
- Esther Melo,
- Philipp Oertle,
- Carolyn Trepp,
- Hélène Meistermann,
- Thomas Burgoyne,
- Lorenzo Sborgi,
- Alvaro Cortes Cabrera,
- Chia-yi Chen,
- Jean-Christophe Hoflack,
- Tony Kam-Thong,
- Roland Schmucki,
- Laura Badi,
- Nicholas Flint,
- Zeynep Eren Ghiani,
- Fréderic Delobel,
- Corinne Stucki,
- Giulia Gromo,
- Alfred Einhaus,
- Benoit Hornsperger,
- Sabrina Golling,
- Juliane Siebourg-Polster,
- Francoise Gerber,
- Bernd Bohrmann,
- Clare Futter,
- Tom Dunkley,
- Sebastian Hiller,
- Oliver Schilling,
- Volker Enzmann,
- Sascha Fauser,
- Marija Plodinec,
- Roberto Iacone
Affiliations
- Esther Melo
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Philipp Oertle
- Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland
- Carolyn Trepp
- Department of Ophthalmology, Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland
- Hélène Meistermann
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Thomas Burgoyne
- Institute of Ophthalmology, University College London, London EC1V9EL, United Kingdom
- Lorenzo Sborgi
- Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland
- Alvaro Cortes Cabrera
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Chia-yi Chen
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg D-79104, Germany
- Jean-Christophe Hoflack
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Tony Kam-Thong
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Roland Schmucki
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Laura Badi
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Nicholas Flint
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Zeynep Eren Ghiani
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Fréderic Delobel
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Corinne Stucki
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Giulia Gromo
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Alfred Einhaus
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Benoit Hornsperger
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Sabrina Golling
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Juliane Siebourg-Polster
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Francoise Gerber
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Bernd Bohrmann
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Clare Futter
- Institute of Ophthalmology, University College London, London EC1V9EL, United Kingdom
- Tom Dunkley
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Sebastian Hiller
- Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland
- Oliver Schilling
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg D-79104, Germany
- Volker Enzmann
- Department of Ophthalmology, Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland
- Sascha Fauser
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- Marija Plodinec
- Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland
- Roberto Iacone
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland
- DOI
- https://doi.org/10.1016/j.ebiom.2017.12.011
- Journal volume & issue
-
Vol. 27,
no. C
pp. 258 – 274
Abstract
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss. The protein HtrA1 is enriched in retinal pigment epithelial (RPE) cells isolated from AMD patients and in drusen deposits. However, it is poorly understood how increased levels of HtrA1 affect the physiological function of the RPE at the intracellular level. Here, we developed hfRPE (human fetal retinal pigment epithelial) cell culture model where cells fully differentiated into a polarized functional monolayer. In this model, we fine-tuned the cellular levels of HtrA1 by targeted overexpression. Our data show that HtrA1 enzymatic activity leads to intracellular degradation of tubulin with a corresponding reduction in the number of microtubules, and consequently to an altered mechanical cell phenotype. HtrA1 overexpression further leads to impaired apical processes and decreased phagocytosis, an essential function for photoreceptor survival. These cellular alterations correlate with the AMD phenotype and thus highlight HtrA1 as an intracellular target for therapeutic interventions towards AMD treatment.
Keywords
- Age-related macular degeneration
- Polarized human retinal, pigmented epithelium
- HtrA serine peptidase 1
- Disease modelling
- Mechanical properties
- Cell stiffness
- Phagocytic activity